Bridging Therapy: How to Safely Switch Between Blood Thinners

Switching between blood thinners isn’t as simple as stopping one pill and starting another. For many people on long-term anticoagulation-especially those with atrial fibrillation, mechanical heart valves, or a history of blood clots-this transition can be risky. Too much anticoagulation? You risk dangerous bleeding. Too little? You could develop a stroke or pulmonary embolism. The middle ground? That’s where bridging therapy comes in. But here’s the twist: for most people today, bridging isn’t needed at all.

What Exactly Is Bridging Therapy?

Bridging therapy means using a fast-acting injectable anticoagulant-like low molecular weight heparin (LMWH) or unfractionated heparin-while temporarily stopping a longer-acting blood thinner like warfarin. It’s meant to keep your blood from clotting during the gap when warfarin’s effects wear off and before you can safely restart it after surgery or a procedure.

Think of it like this: warfarin takes days to build up in your system and days to leave it. If you need surgery and stop warfarin too early, your clotting risk spikes. If you wait too long, you bleed during the procedure. Bridging tries to fill that gap. But recent evidence shows it’s not the safety net we once thought it was.

Why Bridging Isn’t Always Necessary

For years, doctors routinely bridged patients on warfarin before any procedure. The logic seemed sound: don’t let the blood thin out completely. But the 2015 BRIDGE trial changed everything. Researchers tracked over 2,000 patients with atrial fibrillation who stopped warfarin for surgery. Half got heparin bridging. The other half didn’t.

The results? Bridging didn’t lower stroke risk. But it doubled the chance of major bleeding-2.3% vs. 1.0%. That’s not a small difference. It’s life-altering. Since then, guidelines have shifted hard. The American Heart Association now says bridging should only be used for two very specific groups:

• People with mechanical heart valves in the mitral position
• Those who had a blood clot (like a DVT or PE) within the last 3 months

That’s it. For the other 85-90% of people on warfarin-like those with atrial fibrillation without recent clots-bridging does more harm than good. And if you’re on a DOAC (direct oral anticoagulant), you probably don’t need it at all.

DOACs vs. Warfarin: Why One Doesn’t Need Bridging

If you’re on apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban (Savaysa), you’re in a different world. These drugs, called DOACs, work fast and leave fast. Their half-lives range from 5 to 17 hours, depending on kidney function. That means:

• You can stop them 24-48 hours before surgery and know they’re out of your system.
• You can restart them 12-24 hours after surgery, once bleeding risk drops.

No injections. No daily blood tests. No bridging. That’s why DOACs now make up 75% of new anticoagulant prescriptions in 2023. They’re simpler, safer, and better suited to modern life. If you’re still on warfarin because your doctor never switched you, ask why.

When Bridging Is Still Used: The High-Risk Rules

Let’s say you have a mechanical mitral valve. That’s one of the few cases where the risk of clotting outweighs the risk of bleeding. In that case, here’s how bridging typically works:

1. Stop warfarin 5-6 days before surgery. This lets your INR drop below 2.0.
2. Start LMWH (like enoxaparin) 3 days before surgery. Usually given as 1 mg/kg twice daily.
3. Stop the last LMWH dose 24 hours before the procedure. If it’s a high-bleed-risk surgery, you might wait 36 hours.
4. After surgery, restart LMWH 12-24 hours later if there’s no bleeding.
5. Restart warfarin 24 hours after surgery, often at 15-20% higher than your usual dose.
6. Check your INR 3-4 days after restarting warfarin to make sure it’s back in range.

This timeline isn’t guesswork. It’s based on hospital protocols like the one used at Holy Cross Hospital. But even here, it’s not automatic. Your doctor must check your bleeding risk with the HAS-BLED score and your clotting risk with CHA₂DS₂-VASc. If your HAS-BLED score is 3 or higher (think uncontrolled blood pressure, kidney disease, or history of bleeding), bridging may be skipped even with a mechanical valve.

What About Switching from Warfarin to a DOAC?

Maybe your doctor wants to switch you from warfarin to apixaban. This isn’t bridging-it’s conversion. And it’s done differently.

Here’s how it works:

• Stop warfarin and check your INR. If it’s below 2.0, start apixaban the same day.
• If your INR is between 2.0 and 2.5, wait one day before starting apixaban.
• If your INR is above 2.5, delay apixaban until it drops. Don’t rush it.

There’s no need for heparin in between. The DOAC takes over quickly. The same applies if switching from dabigatran to warfarin: start warfarin on the same day you stop dabigatran, and overlap for 5 days while monitoring INR.

The Hidden Dangers of Bridging

Even when bridging is recommended, it’s not without risk. Here’s what most patients don’t realize:

• Injection burden: You’ll need two daily shots for 5-7 days. Many people miss doses or give them incorrectly.
• Cost: A 7-day course of LMWH can cost $300-$500 in the U.S. Insurance doesn’t always cover it fully.
• Timing errors: If you stop the heparin too late, you bleed during surgery. Too early, and you clot.
• Confusion after surgery: Restarting warfarin too soon or too late is a common cause of readmission.

A 2021 study found that 18% of patients on bridging therapy missed at least one injection. That’s not just inconvenient-it’s dangerous.

What You Should Do Next

If you’re on a blood thinner and have a procedure coming up, here’s your action plan:

1. Know which drug you’re on. Warfarin? DOAC? This changes everything.
2. Ask about your risk. Are you in the 10-15% who truly need bridging? Or are you in the 85% who don’t?
3. Request your INR and kidney function numbers. Your doctor needs them to decide.
4. Confirm the plan with your surgeon. Your anticoagulation plan must be coordinated with the surgical team.
5. Get written instructions. Don’t rely on memory. Ask for a printed timeline.

If you’re on warfarin and haven’t been offered a switch to a DOAC, ask why. DOACs reduce the need for monitoring, lower bleeding risk, and eliminate the need for bridging in most cases. They’re not perfect, but for most people, they’re better.

Final Thought: Less Is Often More

For decades, the medical world assumed more anticoagulation meant more safety. We thought bridging was a shield. But the data shows it’s more like a double-edged sword. Today’s best practice isn’t about filling every gap-it’s about avoiding unnecessary risk.

For most people, the safest move is to skip bridging entirely. Let the DOAC do its job. If you’re on warfarin, ask if you really need it. And if you’re scheduled for surgery, make sure your care team has a clear, evidence-based plan-not a default one from 20 years ago.